Objective: An association between cerebral venous sinus thrombosis (CVST) and high altitude has been previously proposed, but limited published data exist to support this association. We investigated 28 cases of CVST occurring at high altitude and sought to describe patient demographics, altitude and acclimatization, hematological laboratory findings, neuroimaging, treatment, and prognosis in these cases. Methods: Twenty-eight cases of symptomatic CVST occurring at high altitude were identified between the months of August 2017 and December 2018, in collaboration with Military Hospital, Rawalpindi and Combined Military Hospital, Skardu (Pakistan). Follow-up visits were performed at 1 and 6 months. Results: Twenty-seven (96%) of the patients were males, and the mean age was 33 years. In total, 32.1% were smokers. The mean NIHSS score on presentation was 5.5. 85.7% of the cases occurred at altitude higher than 8,000 feet. On average 107.8 days were spent at a high altitude prior to CVST. Totally, 71.4% had acclimatized for >2 weeks. The mean hemoglobin (Hb) value was 16.7 g/dL and 50% had d-dimer levels higher than 1,000 ng/mL. On MRI, 25% showed signs of hemorrhage and 14.3% showed infarcts. Treatments provided include low-molecular-weight heparin and Rivaroxaban and were associated with good outcomes. Conclusion: CVST is not uncommon at high altitude (>8,000 feet). It is predominantly a male disease. Most patients have high Hb and high D-dimer levels. The overall outcome was good.

Keywords:
Cerebral venous sinus thrombosis, High altitude, Hypercoagulability
1.
Silvis SM, De Sousa DA, Ferro JM, Coutinho JM. Cerebral venous thrombosis.
Nat Rev Neurol
. 2017 Sep;13(9):555–65.
2.
Devasagayam S, Wyatt B, Leyden J, Kleinig T. Cerebral venous sinus thrombosis incidence is higher than previously thought: a retrospective population-based study.
Stroke
. 2016 Sep;47(9):2180–2.
3.
Coutinho JM, Zuurbier SM, Aramideh M, Stam J. The incidence of cerebral venous thrombosis: a cross-sectional study.
Stroke
. 2012 Dec;43(12):3375–7.
4.
Khattar NK, Zemmar A, Liang Q, Li H, Xing Y, Andrade-Barazarte H, et al. Cerebral Venous Thrombosis at High Altitude: A Retrospective Cohort of Twenty-one Consecutive Patients.
Cureus
. 2019 Jun;11(6):e4940.
5.
Ainslie PN, Subudhi AW. Cerebral blood flow at high altitude.
High Alt Med Biol
. 2014 Jun;15(2):133–40.
6.
Zavanone C, Panebianco M, Yger M, Borden A, Restivo D, Angelini C, et al. Cerebral venous thrombosis at high altitude: a systematic review.
Rev Neurol (Paris)
. 2017 Apr;173(4):189–93.
7.
Syed MJ, Alamgir W, Wasay M. Cerebral venous thrombosis At high altitude. Pakistan J Neurol Sci. 2018;13(3):44–51.
8.
Wasay M, Azeemuddin M. Neuro-imaging of cerebral venous thrombosis.
J Neuroimaging
. 2005 Apr;15(2):118–28.
9.
Ferro JM, Canhão P, Stam J, Bousser MG, Barinagarrementeria F. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT).
Stroke
. 2004 Mar;35(3):664–70.
10.
Coutinho JM, Ferro JM, Canhao P, Barinagarrementeria F, Cantú C, Bousser MG, et al. Cerebral venous and sinus thrombosis in women.
Stroke
. 2009 Jul;40(7):2356–61.
11.
Cheng S, Chng SM, Singh R. Cerebral venous infarction during a high altitude expedition.
Singapore Med J
. 2009 Aug;50(8):e306–8.
12.
Song SY, Asaji T, Tanizaki Y, Fujimaki T, Matsutani M, Okeda R. Cerebral thrombosis at altitude: its pathogenesis and the problems of prevention and treatment.
Aviat Space Environ Med
. 1986 Jan;57(1):71–6.
13.
Torgovicky R, Azaria B, Grossman A, Eliyahu U, Goldstein L. Sinus vein thrombosis following exposure to simulated high altitude.
Aviat Space Environ Med
. 2005 Feb;76(2):144–6.
14.
Boulos P, Kouroukis C, Blake G. Superior sagittal sinus thrombosis occurring at high altitude associated with protein C deficiency.
Acta Haematol
. 1999;102(2):104–6.
15.
Anand AC, Jha SK, Saha A, Sharma V, Adya CM. Thrombosis as a complication of extended stay at high altitude.
Natl Med J India
. 2001 Jan;14(4):197–201.
16.
Saito S, Tanaka SK. A case of cerebral sinus thrombosis developed during a high-altitude expedition to Gasherbrum I.
Wilderness Environ Med
. 2003 Dec;14(4):226–30.
17.
Skaiaa SC, Stave H. Recurrent sagittal sinus thrombosis occurring at high altitude during expeditions to Cho Oyu.
Wilderness Environ Med
. 2006 Jun;17(2):132–6.
18.
Kotwal J, Apte CV, Kotwal A, Mukherjee B, Jayaram J. High altitude: a hypercoagulable state: results of a prospective cohort study.
Thromb Res
. 2007 Jan;120(3):391–7.
19.
Nair V, Mohapatro AK, Sreedhar M, Indrajeet IK, Tewari AK, Anand AC, et al. A case of hereditary protein S deficiency presenting with cerebral sinus venous thrombosis and deep vein thrombosis at high altitude.
Acta Haematol
. 2008;119(3):158–61.
20.
Grabe HM, Bapuraj JR, Wesolowski JR, Parmar H, Trobe JD. Homonymous hemianopia from infarction of the optic tract and lateral geniculate nucleus in deep cerebral venous thrombosis.
J Neuroophthalmol
. 2012 Mar;32(1):38–41.
21.
Shrestha P, Basnyat B, Küpper T, van der Giet S. Cerebral venous sinus thrombosis at high altitude.
High Alt Med Biol
. 2012 Mar;13(1):60–2.
22.
Hassan KM, Kumar D. Reversible diencephalic dysfunction as presentation of deep cerebral venous thrombosis due to hyperhomocysteinemia and protein S deficiency: documentation of a case.
J Neurosci Rural Pract
. 2013 Apr;4(2):193–6.
23.
Nair V, Yanamandra U, Kumud R, Ghosh K. PAI-1 polymorphism as a cause of severe high altitude associated arteriovenous thrombosis.
BMJ Case Rep
. 2016 Nov.pii: bcr2016217361.
24.
Ye DP, Zhang SL, Xu QH, Wei LJ. A case of Galen vein thrombosis occurring after bilateral acetabular fractures in the Tibet plateau–what can we learn?
Chin J Traumatol
. 2017 Oct;20(5):308–10.
25.
Kim JH, Kim SJ, Kim HY. Right Hand Weakness and Headache During Ascent to Mount Everest: A Case of Cerebral Venous Infarction.
Neurologist
. 2017 May;22(3):98–100.
26.
Paliwal AK, Gupta M, Peeyush P, Sharma V. Imaging the diverse presentations of cerebral venous thrombosis occurring at high altitude area in Armed Forces personnel: case series.
Med J Armed Forces India
. 2019 Jul;75(3):282–7.
27.
Fujimaki T, Matsutani M, Asai A, Kohno T, Koike M. Cerebral venous thrombosis due to high-altitude polycythemia. Case report.
J Neurosurg
. 1986 Jan;64(1):148–50.
28.
Jha SK, Anand AC, Sharma V, Kumar N, Adya CM. Stroke at high altitude: indian experience.
High Alt Med Biol
. 2002 Mar;3(1):21–7.
29.
Pfausler B, Vollert H, Bösch S, Schmutzhard E. Cerebral venous thrombosis – a new diagnosis in travel medicine?
J Travel Med
. 1996 Sep;3(3):165–7.
30.
Khan ID. Cerebral venous sinus thrombosis masquerading as high altitude cerebral edema at extreme altitude.
Int J Travel Med Global Health
. 2016 Sep;4(3):96–8.
31.
Khanal P, Thapa L, Shrestha AM, Bhattarai S, Sapkota D, Sharma N, et al. Cerebral venous sinus thrombosis during Everest expedition: a case report and review of the literature.
Case Rep Neurol Med
. 2016;2016:8314040.
32.
Smith JR, Landaw SA. Smokers’ polycythemia.
N Engl J Med
. 1978 Jan;298(1):6–10.
33.
Saqib MAN, Rafique I, Qureshi H, Munir MA, Bashir R, Arif BW, et al. Burden of Tobacco in Pakistan: Findings From Global Adult Tobacco Survey 2014.
Nicotine Tob Res
. 2018 Aug 14;20(9):1138–43.
34.
Liu K, Pei L, Gao Y, Zhao L, Fang H, Bunda B, et al. Dehydration Status Predicts Short-Term and Long-Term Outcomes in Patients with Cerebral Venous Thrombosis.
Neurocrit Care
. 2019 Apr;30(2):478–83.
35.
Pichler Hefti J, Risch L, Hefti U, Scharrer I, Risch G, Merz TM, et al. Changes of coagulation parameters during high altitude expedition.
Swiss Med Wkly
. 2010;140(7-8):111–7.
36.
Dentali F, Squizzato A, Marchesi C, Bonzini M, Ferro JM, Ageno W. D-dimer testing in the diagnosis of cerebral vein thrombosis: a systematic review and a meta-analysis of the literature.
J Thromb Haemost
. 2012 Apr;10(4):582–9.
37.
Hiltunen S, Putaala J, Haapaniemi E, Salonen O, Tatlisumak T. D-dimer and clinicoradiologic features in cerebral venous thrombosis.
J Neurol Sci
. 2013 Apr;327(1-2):12–4.
38.
Luo Y, Tian X, Wang X. Diagnosis and treatment of cerebral venous thrombosis: A review.
Front Aging Neurosci
. 2018 Jan;10:2.
39.
Liang J, Chen H, Li Z, He S, Luo B, Tang S, et al. Cortical vein thrombosis in adult patients of cerebral venous sinus thrombosis correlates with poor outcome and brain lesions: a retrospective study.
BMC Neurol
. 2017 Dec;17(1):219.
40.
Einhäupl K, Stam J, Bousser MG, De Bruijn SF, Ferro JM, Martinelli I, et al. EFNS guideline on the treatment of cerebral venous and sinus thrombosis in adult patients.
Eur J Neurol
. 2010 Oct;17(10):1229–35.
41.
Coutinho J, de Bruijn SF, Deveber G, Stam J. Anticoagulation for cerebral venous sinus thrombosis.
Cochrane Database Syst Rev
. 2011 Aug;(8):CD002005.
42.
Misra UK, Kalita J, Chandra S, Kumar B, Bansal V. Low molecular weight heparin versus unfractionated heparin in cerebral venous sinus thrombosis: a randomized controlled trial.
Eur J Neurol
. 2012 Jul;19(7):1030–6.
43.
Afshari D, Moradian N, Nasiri F, Razazian N, Bostani A, Sariaslani P. The efficacy and safety of low-molecular-weight heparin and unfractionated heparin in the treatment of cerebral venous sinus thrombosis.
Neurosciences (Riyadh)
. 2015 Oct;20(4):357–61.
44.
Geisbüsch C, Richter D, Herweh C, Ringleb PA, Nagel S. Novel factor xa inhibitor for the treatment of cerebral venous and sinus thrombosis: first experience in 7 patients.
Stroke
. 2014 Aug;45(8):2469–71.
45.
Ferro JM, Coutinho JM, Dentali F, Kobayashi A, Alasheev A, Canhão P, et al.; RE-SPECT CVT Study Group. Safety and Efficacy of Dabigatran Etexilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis: A Randomized Clinical Trial.
JAMA Neurol
. 2019, Epub ahead of print.
46.
Wasay M, Khan M, Majid H, Farooq S, Memon I, AlRukn S, et al. New Oral Anticoagulants versus Warfarin for Cerebral Venous Thrombosis: A Multi-Center, Observational Study.
J Stroke
. 2019;21(21):220–3.
47.
de Bruijn SF, De Haan RJ, Stam J. Clinical features and prognostic factors of cerebral venous sinus thrombosis in a prospective series of 59 patients. For The Cerebral Venous Sinus Thrombosis Study Group.
J Neurol Neurosurg Psychiatry
. 2001 Jan;70(1):105–8.
48.
Sassi SB, Touati N, Baccouche H, Drissi C, Romdhane NB, Hentati F. Cerebral venous thrombosis: a tunisian monocenter study on 160 patients.
Clin Appl Thromb Hemost
. 2017 Nov;23(8):1005–9.
49.
Lee DJ, Ahmadpour A, Binyamin T, Dahlin BC, Shahlaie K, Waldau B. Management and outcome of spontaneous cerebral venous sinus thrombosis in a 5-year consecutive single-institution cohort.
J Neurointerv Surg
. 2017 Jan;9(1):34–8.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.